細胞和基因治療生產品質控制市場－全球產業規模、佔有率、趨勢、機會及預測（按治療類型、產品、製程、技術、應用、地區和競爭格局分類），2021-2031年

全球細胞和基因治療生產品管市場預計將從 2025 年的 13.5 億美元成長到 2031 年的 20.1 億美元，複合年成長率為 6.87%。

該領域著重嚴格的分析測試和監管合規流程，以檢驗先進醫療產品的安全性、有效性、純度和特性。該市場的成長主要得益於臨床試驗數量的快速增加以及針對腫瘤和罕見遺傳疾病的治療方法監管核准速度的不斷提高。這些因素使得實施全面的品質保證架構勢在必行，以便在商業化規模生產中，既能應對生物製藥的天然變異性，又能滿足嚴格的安全標準。

根據美國基因與細胞治療學會的數據，到2024年，全球在開發平臺將超過4000種，這將對專業檢測通訊協定產生顯著需求。儘管市場成長勢頭強勁，但仍面臨許多挑戰，包括開發標準化效力檢測法的技術複雜性和高成本。這些挑戰往往會延長生產週期，增加整體銷貨成本，阻礙因素市場擴張。

市場促進因素

生物製藥研發領域資金和投資的湧入，從根本上加速了細胞和基因治療（CGT）領域先進品管方法的應用。隨著研發人員努力將複雜的治療方法商業化，大量資金正被投入到推進臨床試驗以及建立穩健、擴充性的生產和檢測基礎設施。這種雄厚的資金實力使企業能夠購買高階分析設備，並檢驗符合監管要求的快速檢測方法。據再生醫學聯盟（Alliance for Regenerative Medicine）稱，該領域的資金籌措在2024年10月再次活躍起來，僅上半年全球投資就達到了109億美元。這些資金對於克服生產瓶頸以及滿足日益增加的後期候選藥物不斷變化的品管需求至關重要。

第二個關鍵促進因素是將自動化和數位化融入品管工作流程，這直接滿足了產業對更高準確性和更少誤差的需求。透過以自動化平台取代勞力密集的手動測試，製造商正在提高資料完整性，並縮短無菌性和有效性測試結果的報告時間。大型製藥企業為獲得自動化生產能力而進行的合作，充分體現了這種轉變。例如，Fierce Pharma在2024年4月報道稱，百時美施貴寶公司簽署了一項價值3.8億美元的協議，以確保在Cellares的全自動平台上獲得獨家生產能力。監管方面的進展進一步強化了這一趨勢。例如，正如PharmaBoardroom在2024年4月報導的那樣，預計2023年將有創紀錄的7種細胞和基因治療藥物獲得FDA核准，這凸顯了滿足商業性需求的自動化合規品管解決方案的緊迫性。

市場挑戰

開發標準化的效力檢測方法涉及複雜的技術要求和高昂的成本，這嚴重阻礙了全球細胞和基因治療生產品管市場的發展。先進治療方法固有的高生物變異性常常迫使製造商設計客製化的檢測通訊協定來檢驗產品效力，而不是依賴現成的標準。這種缺乏標準化的做法導致了昂貴且耗時的研發週期，顯著增加了產品成本 (COGS) 並延長了生產週期。這些問題常常導致法規核准延誤，因為化學、生產和控制 (CMC) 方面的缺陷會阻礙產品進入商業化階段，並妨礙透過廣泛的品管檢測產生收入。

2024年，再生醫學聯盟預計全球將有多達17種新型細胞和基因療法獲得監管部門核准，這將標誌著大量商業產品的湧入，並對品管系統構成巨大壓力。然而，目前效力檢測法的低效性造成了瓶頸，阻礙了此潛在產量的實現。因此，高昂的檢測成本和技術壁壘正在延緩候選療法向可規模化商業化生產的轉化，直接阻礙了市場擴張。

市場趨勢

一個顯著的行業趨勢是，由於複雜病毒載體和細胞療法的表徵技術要求高，生物製藥公司越來越依賴將專業的品管測試外包給合約研發生產機構（CDMO）。生物製藥公司不再為每種治療方法建立高成本的內部測試體系，而是利用CDMO成熟的監管專業知識和可擴展的基礎設施來加快批次放行。這種生產和測試資源的整合也反映在市場趨勢中。例如，根據BioPharma Dive報道，Novo Holdings於2024年12月以165億美元收購Catalent, Inc.，這表明該行業越來越依賴外部合作夥伴來管理日益成長的、規模更大、複雜性更高的先進療法生產。

同時，人工智慧在預測性品質分析領域的應用正成為一股變革力量，它超越了簡單的數位化，能夠最佳化上游工程和下游流程。透過分析來自生物反應器的大量資料集，製造商利用機器學習演算法識別關鍵的品質偏差或代謝變化，從而在批次失效之前將其識別出來，保護寶貴的庫存。鑑於自體療法生產成本高昂，這種預測能力正變得至關重要。根據澳洲IT簡報2025年9月發布的報告，生產錯誤帶來的巨大財務風險——單一細胞療法批次的成本可能超過50萬美元——正推動著人工智慧驅動的即時監控技術在商業性可行性方面的應用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球細胞與基因治療生產品質管制市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依治療方法（細胞療法、基因療法）
  • 依所提供服務的類型（設備、耗材、其他）
  • 按流程（原料準備、上游工程、下​​游加工、包裝）
  • 透過技術（聚合酵素鏈鎖反應（PCR）、流式細胞技術、鱟變形細胞裂解物（LAL）、酵素免疫分析法（ELISA）、層析法、質譜法、蛋白質印跡法、次世代定序（NGS）、電泳法、其他）
  • 按應用領域（安全性測試、有效性測試、鑑別測試、穩定性測試和遺傳保真度測試等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美細胞與基因治療生產品質管制市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲細胞和基因治療生產品質控制市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區細胞與基因治療生產品質控制市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲細胞與基因治療生產品質控制市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美細胞與基因治療生產品質管制市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球細胞與基因治療生產品質管制市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Bio-Techne Corporation
• Biomerieux SA
• F. Hoffmann-La Roche Ltd
• Lonza Group Ltd.
• Miltenyi Biotec India Pvt Ltd.
• Sartorius AG
• Thermo Fisher Scientific Inc.
• AGC Inc.
• Charles River Laboratories International, Inc.
• Merck KGaA

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Cell and Gene Therapy Manufacturing QC Market is projected to expand from USD 1.35 Billion in 2025 to USD 2.01 Billion by 2031, reflecting a compound annual growth rate of 6.87%. This sector focuses on stringent analytical testing and regulatory adherence processes designed to verify the safety, potency, purity, and identity of advanced medicinal products. The market is primarily underpinned by a surge in clinical trial volumes and an increasing rate of regulatory approvals for therapies targeting oncology and rare genetic disorders. These drivers necessitate the implementation of comprehensive quality assurance frameworks to manage the natural variability of biologic materials while ensuring rigorous safety standards are met during commercial scale-up.

Data from the American Society of Gene and Cell Therapy indicates that in 2024, the global development pipeline contained more than 4,000 therapeutic candidates, generating substantial demand for specialized testing protocols. Despite this robust growth trajectory, the market faces a significant obstacle regarding the technical complexity and high costs associated with creating standardized potency assays. These challenges often prolong production timelines and inflate the overall cost of goods sold, acting as a constraint on broader market expansion.

Market Driver

Significant capital inflows and investments in biopharmaceutical R&D are fundamentally accelerating the adoption of advanced quality control measures within the cell and gene therapy (CGT) sector. As developers strive to commercialize complex therapies, vast financial resources are being allocated to clinical progression as well as the establishment of robust, scalable manufacturing and testing infrastructures. This financial strength enables companies to acquire high-end analytical instruments and validate the rapid testing methods required for regulatory compliance. According to the Alliance for Regenerative Medicine, the sector saw a resurgence in financing in October 2024, with global investments reaching $10.9 billion in the first half of the year alone, funding that is crucial for overcoming manufacturing bottlenecks and aligning quality control evolution with the increasing number of late-stage candidates.

A second critical driver is the integration of automation and digitalization into quality control workflows, which directly addresses the industry's need for precision and error reduction. By replacing labor-intensive manual assays with automated platforms, manufacturers are enhancing data integrity and reducing turnaround times for sterility and potency results. This shift is exemplified by major pharmaceutical collaborations aiming to secure automated production capacities; for instance, Fierce Pharma reported in April 2024 that Bristol Myers Squibb signed a $380 million deal to reserve exclusive capacity on Cellares' fully automated platform. This trend is further reinforced by regulatory successes, such as the record seven new FDA approvals for cell and gene therapies in 2023 noted by PharmaBoardroom in April 2024, underscoring the urgency for automated, compliant QC solutions to meet commercial demand.

Market Challenge

The intricate technical requirements and high costs involved in developing standardized potency assays constitute a formidable barrier to the growth of the Global Cell and Gene Therapy Manufacturing QC Market. Due to the significant biological variability inherent in advanced therapies, manufacturers are often compelled to design bespoke testing protocols to verify product potency rather than utilizing off-the-shelf standards. This lack of standardization requires expensive, labor-intensive development cycles that significantly increase the overall cost of goods sold (COGS) and extend production timelines. These issues frequently lead to regulatory delays, as deficiencies in Chemistry, Manufacturing, and Controls (CMC) can prevent products from advancing to the commercial stage where high-volume quality control testing generates revenue.

In 2024, the Alliance for Regenerative Medicine anticipated up to 17 regulatory approvals for new cell and gene therapies globally, signaling an influx of commercial products that places acute pressure on quality control systems. However, the inefficiency of current potency assays creates a bottleneck that stifles this potential throughput. Consequently, market expansion is directly impeded, as high testing costs and technical hurdles slow the transition of therapeutic candidates into scalable commercial production.

Market Trends

A dominant trend in the industry is the increasing reliance on outsourcing specialized QC assays to Contract Development and Manufacturing Organizations (CDMOs), driven by the technical demands of characterizing complex viral vectors and cell therapies. Rather than constructing expensive in-house testing capabilities for every modality, biopharmaceutical companies are leveraging the established regulatory expertise and scalable infrastructure of CDMOs to accelerate batch release. This consolidation of manufacturing and testing resources is illustrated by significant market movements, such as Novo Holdings' pivotal $16.5 billion acquisition of Catalent in December 2024, as reported by BioPharma Dive, which underscores the sector's strategic reliance on external partners to manage the growing volume and complexity of advanced therapeutic production.

Simultaneously, the application of artificial intelligence for predictive quality analytics is emerging as a transformative force, moving beyond simple digitization to optimize both upstream and downstream processes. Manufacturers are utilizing machine learning algorithms to analyze vast datasets from bioreactors, allowing for the identification of critical quality deviations and metabolic shifts before they result in batch failure, thereby protecting expensive inventory. This predictive capability is becoming financially imperative given the high costs associated with manufacturing autologous treatments; according to IT Brief Australia in September 2025, the substantial financial risk of production errors-where a single cell therapy batch can cost upwards of $500,000-is driving the adoption of AI-driven real-time monitoring for commercial viability.

Key Market Players

• Bio-Techne Corporation
• Biomerieux SA
• F. Hoffmann-La Roche Ltd
• Lonza Group Ltd.
• Miltenyi Biotec India Pvt Ltd.
• Sartorius AG
• Thermo Fisher Scientific Inc.
• AGC Inc.
• Charles River Laboratories International, Inc.
• Merck KGaA

Report Scope

In this report, the Global Cell and Gene Therapy Manufacturing QC Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell and Gene Therapy Manufacturing QC Market, By Therapy Type

• Cell Therapy
• Gene Therapy

Cell and Gene Therapy Manufacturing QC Market, By Offering

• Instruments
• Consumables
• Others

Cell and Gene Therapy Manufacturing QC Market, By Process

• Raw Material Preparation
• Upstream Processing
• Downstream Processing
• Packaging

Cell and Gene Therapy Manufacturing QC Market, By Technology

• Polymerase Chain Reaction (PCR)
• Flow Cytometry
• Limulus Amebocyte Lysate (LAL)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Chromatography
• Mass Spectrometry
• Western Blotting
• Next-Generation Sequencing (NGS)
• Electrophoresis
• Others

Cell and Gene Therapy Manufacturing QC Market, By Application

• Safety Testing
• Potency Testing
• Identity Testing
• Stability and Genetic Fidelity Testing
• Others

Cell and Gene Therapy Manufacturing QC Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell and Gene Therapy Manufacturing QC Market.

Available Customizations:

Global Cell and Gene Therapy Manufacturing QC Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell and Gene Therapy Manufacturing QC Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Cell Therapy, Gene Therapy)
  • 5.2.2. By Offering (Instruments, Consumables, Others)
  • 5.2.3. By Process (Raw Material Preparation, Upstream Processing, Downstream Processing, Packaging)
  • 5.2.4. By Technology (Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), Electrophoresis, Others)
  • 5.2.5. By Application (Safety Testing, Potency Testing, Identity Testing, Stability and Genetic Fidelity Testing, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Cell and Gene Therapy Manufacturing QC Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Offering
  • 6.2.3. By Process
  • 6.2.4. By Technology
  • 6.2.5. By Application
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Offering
      • 6.3.1.2.3. By Process
      • 6.3.1.2.4. By Technology
      • 6.3.1.2.5. By Application
  • 6.3.2. Canada Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Offering
      • 6.3.2.2.3. By Process
      • 6.3.2.2.4. By Technology
      • 6.3.2.2.5. By Application
  • 6.3.3. Mexico Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Offering
      • 6.3.3.2.3. By Process
      • 6.3.3.2.4. By Technology
      • 6.3.3.2.5. By Application

7. Europe Cell and Gene Therapy Manufacturing QC Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Offering
  • 7.2.3. By Process
  • 7.2.4. By Technology
  • 7.2.5. By Application
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Offering
      • 7.3.1.2.3. By Process
      • 7.3.1.2.4. By Technology
      • 7.3.1.2.5. By Application
  • 7.3.2. France Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Offering
      • 7.3.2.2.3. By Process
      • 7.3.2.2.4. By Technology
      • 7.3.2.2.5. By Application
  • 7.3.3. United Kingdom Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Offering
      • 7.3.3.2.3. By Process
      • 7.3.3.2.4. By Technology
      • 7.3.3.2.5. By Application
  • 7.3.4. Italy Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Offering
      • 7.3.4.2.3. By Process
      • 7.3.4.2.4. By Technology
      • 7.3.4.2.5. By Application
  • 7.3.5. Spain Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Offering
      • 7.3.5.2.3. By Process
      • 7.3.5.2.4. By Technology
      • 7.3.5.2.5. By Application

8. Asia Pacific Cell and Gene Therapy Manufacturing QC Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Offering
  • 8.2.3. By Process
  • 8.2.4. By Technology
  • 8.2.5. By Application
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Offering
      • 8.3.1.2.3. By Process
      • 8.3.1.2.4. By Technology
      • 8.3.1.2.5. By Application
  • 8.3.2. India Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Offering
      • 8.3.2.2.3. By Process
      • 8.3.2.2.4. By Technology
      • 8.3.2.2.5. By Application
  • 8.3.3. Japan Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Offering
      • 8.3.3.2.3. By Process
      • 8.3.3.2.4. By Technology
      • 8.3.3.2.5. By Application
  • 8.3.4. South Korea Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Offering
      • 8.3.4.2.3. By Process
      • 8.3.4.2.4. By Technology
      • 8.3.4.2.5. By Application
  • 8.3.5. Australia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Offering
      • 8.3.5.2.3. By Process
      • 8.3.5.2.4. By Technology
      • 8.3.5.2.5. By Application

9. Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Offering
  • 9.2.3. By Process
  • 9.2.4. By Technology
  • 9.2.5. By Application
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Offering
      • 9.3.1.2.3. By Process
      • 9.3.1.2.4. By Technology
      • 9.3.1.2.5. By Application
  • 9.3.2. UAE Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Offering
      • 9.3.2.2.3. By Process
      • 9.3.2.2.4. By Technology
      • 9.3.2.2.5. By Application
  • 9.3.3. South Africa Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Offering
      • 9.3.3.2.3. By Process
      • 9.3.3.2.4. By Technology
      • 9.3.3.2.5. By Application

10. South America Cell and Gene Therapy Manufacturing QC Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Offering
  • 10.2.3. By Process
  • 10.2.4. By Technology
  • 10.2.5. By Application
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell and Gene Therapy Manufacturing QC Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Offering
      • 10.3.1.2.3. By Process
      • 10.3.1.2.4. By Technology
      • 10.3.1.2.5. By Application
  • 10.3.2. Colombia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Offering
      • 10.3.2.2.3. By Process
      • 10.3.2.2.4. By Technology
      • 10.3.2.2.5. By Application
  • 10.3.3. Argentina Cell and Gene Therapy Manufacturing QC Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Offering
      • 10.3.3.2.3. By Process
      • 10.3.3.2.4. By Technology
      • 10.3.3.2.5. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell and Gene Therapy Manufacturing QC Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Bio-Techne Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Biomerieux SA
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Lonza Group Ltd.
• 15.5. Miltenyi Biotec India Pvt Ltd.
• 15.6. Sartorius AG
• 15.7. Thermo Fisher Scientific Inc.
• 15.8. AGC Inc.
• 15.9. Charles River Laboratories International, Inc.
• 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer